title: Acute lung affection in an endurance-trained man under amiodarone medication.
abstract: Patients undergoing treatment with amiodarone can develop severe pulmonary side effects. This effect, which is often highly underestimated, can lead to dyspnea, pneumonitis, and further fibrosis. A recent change in the labeling of amdiodarone by the American Food and Drug Administration (FDA) supports this suspicion. Tracing the symptoms back to the causing agent can be difficult, as shown in our report. The subject of this case report is an endurance-trained 65 year old male marathon runner who appeared with atrial fibrillation during a routine check up in autumn 2003. After medical cardioversion with flecainide a complaint free interval of 8 months was followed by a relapse, which resulted in a change of medication to amiodarone. Due to misunderstandings the patient kept on taking the amiodarone loading dose for six weeks and returned with severe dyspnea on exertion. Losses in CO diffusing capacity, a lowered macrophages count and a positive lymphocyte transformation test were the only first hand clinical evidence of amiodarone intoxication, despite the sensation of dyspnea. This case shows that special care has to be taken in treatment with amiodarone. Side effects can be hard to trace and do not evidently show a clear connection to amiodarone.
authors.affiliation: University Clinic Freiburg, Department of Pneumology, Freiburg, Germany.
authors.forename: Stephan
authors.initials: S
authors.lastname: Walterspacher
authors.forename: Wolfram
authors.initials: W
authors.lastname: Windisch
authors.forename: Gernot
authors.initials: G
authors.lastname: Zissel
authors.forename: Bernward
authors.initials: B
authors.lastname: Saurbier
authors.forename: Stephan
authors.initials: S
authors.lastname: Sorichter
references.citation: Chest. 2004 Apr;125(4):1591-2
references.pmid: 15078784
references.citation: Am J Clin Pathol. 1987 Jan;87(1):7-13
references.pmid: 3799544
references.citation: Eur Respir J Suppl. 2001 Sep;32:93s-100s
references.pmid: 11816828
references.citation: Chest. 2003 Feb;123(2):646-51
references.pmid: 12576397
references.citation: Dtsch Med Wochenschr. 1996 Nov 22;121(47):1462-6
references.pmid: 8983896
references.citation: Can Respir J. 2000 Mar-Apr;7(2):193-7
references.pmid: 10859406
references.citation: Chest. 2001 Jul;120(1):275-82
references.pmid: 11451849
references.citation: Am J Med. 1989 Jan;86(1):4-10
references.pmid: 2910095
references.citation: Chest. 1992 Oct;102(4):999-1004
references.pmid: 1395816
references.citation: Chest. 1984 Oct;86(4):541-8
references.pmid: 6478892
references.citation: J Allergy Clin Immunol. 1991 Jul;88(1):54-60
references.pmid: 2071785
references.citation: Eur J Med Res. 1999 Feb 25;4(2):67-71
references.pmid: 10066642
references.citation: Respiration. 2003 May-Jun;70(3):310-2
references.pmid: 12915754
references.citation: J Pharmacol Exp Ther. 2001 Sep;298(3):1280-9
references.pmid: 11504831
references.citation: Pharmacotherapy. 1998 Nov-Dec;18(6 Pt 2):138S-145S
references.pmid: 9855346
references.citation: Proc Soc Exp Biol Med. 1996 Sep;212(4):297-304
references.pmid: 8751986
references.citation: Am J Cardiol. 1989 Dec 1;64(19):1322-6
references.pmid: 2589198
references.citation: Circulation. 1990 Jul;82(1):51-9
references.pmid: 2364524
references.citation: Postgrad Med J. 1994 Jul;70(825):492-8
references.pmid: 7937427
references.citation: Chest. 1988 Feb;93(2):254-63
references.pmid: 3338292
references.citation: Pneumologie. 2002 Jan;56(1):31-5
references.pmid: 11797156